RT Book, Section
A1 Patterson, Briana C.
A1 Meacham, Lillian R.
A2 Sarafoglou, Kyriakie
A2 Hoffmann, Georg F.
A2 Roth, Karl S.
SR Print(0)
ID 1140324700
T1 Endocrine Problems in Pediatric Cancer Survivors
T2 Pediatric Endocrinology and Inborn Errors of Metabolism, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071773140
LK accesspediatrics.mhmedical.com/content.aspx?aid=1140324700
RD 2024/04/20
AB Survival  rates  for  pediatric  cancers  continue  to  improve.  Overall  5-year  survival  for  all  types  has  increased  from  58.1%  for  childhood  cancers  diagnosed  in  the  1970s  to  82.5%  for  those  diagnosed  between  2001  and  2007.1,2  As  a  result,  the  population  of  childhood  cancer  survivors  expands,  and  it  is  estimated  1:570  young  adults  living  in  the  United  States  is  a  survivor  of  childhood  cancer.3  However,  curative  cancer  treatment  comes  with  a  price;  radiation,  chemotherapy,  surgery,  and  bone  marrow  transplant  (BMT)  can  all  negatively  affect  endocrine  function.  In  many  cases,  children  are  treated  with  multimodal  therapy  and  may  be  at  risk  for  multiple  endocrine  late  effects.  Complications  of  cancer  therapy  may  be  acute-onset  and  transient,  like  weight  loss;  acute-onset  and  chronic,  like  acute  ovarian  failure;  or  late  in  onset,  like  infertility  and  hypothyroidism.